EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS

Gabrielle B Rocque, Joanne L Blum, Yan Ji, Timothy Pluard, John Migas, Shailendra Lakhanpal, Erin Jepsen, Eric Gauthier, Yao Wang, Monica Z Montelongo, Joseph C Cappelleri, Meghan S Karuturi und 1 weitere

Breast Cancer Research and Treatment · 2025-02 · 209 (3) · 613-627

DOI: 10.1007/s10549-024-07524-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 25.11.2024. Verfasst von Gabrielle B Rocque und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham, Birmingham, AL, USA. grocque@uabmc.edu. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Quality of Life. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate patient-reported health-related quality-of-life (QoL) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced/metastatic breast cancer (ABC) treated with palbociclib in the longitudinal real-world study, POLARIS.

Methods

Data were prospectively collected from adult patients with HR+/HER2− ABC treated with palbociclib plus endocrine therapy (ET) in routine clinical practice. QoL was assessed with the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (EORTC QLQ-C30) and reported at baseline and months 6, 12, and 18. Data were expressed as absolute scores at a given time and change from baseline for global QoL and functional/symptom scales. Global Heath Status (GHS)/QoL scores were also determined across 6 patient subgroup categories (e.g., age, visceral disease status). Additionally, the proportions of patients with scores below (functional scales) or above (symptom scales) EORTC-validated thresholds reflecting clinical importance of a health problem were determined.

Results

Among patients treated with palbociclib plus ET (N = 1250) who completed questionnaires at any of the study timepoints, mean GHS/QoL scores at months 6 (69.3), 12 (70.1), and 18 (69.9) were higher than baseline (64.0). Similar trends were observed for functional and symptom scales. Mean GHS/QoL scores over time were consistent across the evaluated subgroups. Decreases in the proportions of patients with clinically important functional impairment/symptoms were observed for most functional/symptom scales from baseline through month 18.

Conclusion

Findings from this real-world study indicate patients with HR+/HER2− ABC treated with palbociclib plus ET maintain their QoL for at least 18 months. Clinical Trial Registration: NCT03280303; registered 12 September 2017

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsQuality of LifeAdultAgedAged, 80 and overFemaleHumansMiddle AgedLongitudinal StudiesPiperazinesProspective StudiesPyridinesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneSurveys and Questionnaires

Stichwörter der Autor:innen

HR+/HER2− advanced breast cancerPOLARISPalbociclibPatient-reported outcomesQuality of lifeReal-world evidence

Substanzen

PiperazinesPyridinesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, humanpalbociclib

Autor:innen und Institutionen

  • University of Alabama at Birmingham, Birmingham, AL, USA. grocque@uabmc.edu.
  • Baylor-Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX, USA.
  • Health Partners Institute, St. Paul, MN, USA.
  • Saint Luke's Cancer Institute, Kansas City, MO, USA.
  • Mid-Illinois Hematology &, Oncology Associates Ltd, Normal, IL, USA.
  • Saint Vincent's Birmingham, Birmingham, AL, USA.

Zitieren

APA

Rocque, G. B., Blum, J. L., Ji, Y., Pluard, T., Migas, J., Lakhanpal, S., Jepsen, E., Gauthier, E., Wang, Y., Montelongo, M. Z., Cappelleri, J. C., Karuturi, M. S., & Tripathy, D. (2025). Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Research and Treatment, 209(3), 613-627. https://doi.org/10.1007/s10549-024-07524-2

Vancouver

Rocque GB, Blum JL, Ji Y, Pluard T, Migas J, Lakhanpal S, et al. Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Research and Treatment. 2025;209(3):613-627. doi:10.1007/s10549-024-07524-2

BibTeX
@article{Rocque2025,
  author = {Rocque, Gabrielle B and Blum, Joanne L and Ji, Yan and Pluard, Timothy and Migas, John and Lakhanpal, Shailendra and Jepsen, Erin and Gauthier, Eric and Wang, Yao and Montelongo, Monica Z and Cappelleri, Joseph C and Karuturi, Meghan S and Tripathy, Debu},
  title = {Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS},
  journal = {Breast Cancer Research and Treatment},
  year = {2025},
  volume = {209},
  number = {3},
  pages = {613--627},
  doi = {10.1007/s10549-024-07524-2}
}
Kostenlos starten →